Thomas Jaquin

Thomas Jaquin

Company: Pieris

Job title: Principle Scientist & In Vivo Team Leader

Seminars:

Simultaneous Costimulatory T-cell Engagement & Checkpoint Inhibition by PRS-344/S095012, a 4-1BB/PD-L1 Bispecific Compound for Tumour-Localized Activation of the Immune System 9:30 am

Overcoming 1st generation 4-1BB agonist safety and efficacy drawbacks with a 4-1BB/PD-L1 bispecific Anticalin® protein/mAb fusion protein Harnessing 4-1BB localized activity in the TME, while also offering the benefit of checkpoint inhibition Preclinical data package to guide clinical studyRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.